The estimated Net Worth of Andrew L Finn is at least $7.71 million dollars as of 20 February 2015. Andrew Finn owns over 105,063 units of Biodelivery Sciences International stock worth over $3,779,550 and over the last 18 years Andrew sold BDSI stock worth over $3,931,256.
Andrew has made over 11 trades of the Biodelivery Sciences International stock since 2009, according to the Form 4 filled with the SEC. Most recently Andrew exercised 105,063 units of BDSI stock worth $587,302 on 20 February 2015.
The largest trade Andrew's ever made was selling 143,679 units of Biodelivery Sciences International stock on 24 January 2014 worth over $1,297,421. On average, Andrew trades about 25,474 units every 104 days since 2007. As of 20 February 2015 Andrew still owns at least 676,127 units of Biodelivery Sciences International stock.
You can see the complete history of Andrew Finn stock trades at the bottom of the page.
Andrew's mailing address filed with the SEC is C/O ARIUS PHARMACEUTICALS, INC., 3100 STONE GAP COURT, RALEIGH, NC, 27612.
Over the last 21 years, insiders at Biodelivery Sciences International have traded over $111,671,776 worth of Biodelivery Sciences International stock and bought 1,813,177 units worth $5,352,510 . The most active insiders traders include International, L.P. Elliott, Associates, L.P. Elliott et Healthcare Master Fund Ltd .... On average, Biodelivery Sciences International executives and independent directors trade stock every 18 days with the average trade being worth of $420,648. The most recent stock trade was executed by Jeffrey Allen Bailey on 9 March 2022, trading 5,333 units of BDSI stock currently worth $29,811.
BioDelivery Sciences International, Inc. is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI has built a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs. BDSI's marketed products address serious and debilitating conditions, including chronic pain and opioid-induced constipation.
Biodelivery Sciences International executives and other stock owners filed with the SEC include: